Mark S. Harvey

1.2k total citations
13 papers, 995 citations indexed

About

Mark S. Harvey is a scholar working on Biochemistry, Molecular Biology and Oncology. According to data from OpenAlex, Mark S. Harvey has authored 13 papers receiving a total of 995 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Biochemistry, 3 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Mark S. Harvey's work include Blood transfusion and management (5 papers), CAR-T cell therapy research (2 papers) and Platelet Disorders and Treatments (2 papers). Mark S. Harvey is often cited by papers focused on Blood transfusion and management (5 papers), CAR-T cell therapy research (2 papers) and Platelet Disorders and Treatments (2 papers). Mark S. Harvey collaborates with scholars based in Netherlands, United Kingdom and Greece. Mark S. Harvey's co-authors include Anneke Brand, L.L.M. Van Deenen, K.W.A. Wirtz, George M. Helmkamp, Leo M.G. van de Watering, J. Hermans, Pieter J. van den Broek, J. G. A. Houbiers, F. Boer and Hans A. Huysmans and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Circulation.

In The Last Decade

Mark S. Harvey

13 papers receiving 938 citations

Peers

Countries citing papers authored by Mark S. Harvey

Since Specialization

Citations

This map shows the geographic impact of Mark S. Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Harvey more than expected).

Fields of papers citing papers by Mark S. Harvey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Harvey. The network helps show where Mark S. Harvey may publish in the future.

Co-authorship network of co-authors of Mark S. Harvey

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Harvey. A scholar is included among the top collaborators of Mark S. Harvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Harvey. Mark S. Harvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Chimerism occurs in thyroid, lung, skin and lymph nodes of women with sons 2008 ·Journal of Reproductive Immunology ·Marion Koopmans, Idske C. L. Kremer Hovinga, Hans J. Baelde, Mark S. Harvey, Emile de Heer, Jan A. Bruijn, Ingeborg M. Bajema	37
2	Coagulation parameters of thawed fresh‐frozen plasma during storage at different temperatures 2007 ·Transfusion Medicine ·(unknown), Dennis C.W. Poland, Jeroen Eikenboom, Mark S. Harvey, (unknown), Anneke Brand, René R. P. de Vries	58
3	A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma 2006 ·Blood ·Jean‐Louis Kerkhoffs, Jeroen Eikenboom, (unknown), (unknown), Ronald Brand, Mark S. Harvey, R R de Vries, Renée M. Y. Barge, D.J. van Rhenen, Anneke Brand	100
4	Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy 2004 ·Journal of Clinical Oncology ·T. Geldart, Mark S. Harvey, Norman J. Carr, Martin J. Glennie, Peter Johnson	2
5	Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy 2004 ·Journal of Clinical Oncology ·T. Geldart, Mark S. Harvey, Norman J. Carr, M J Glennie, Peter Johnson	5
6	Beneficial Effects of Leukocyte Depletion of Transfused Blood on Postoperative Complications in Patients Undergoing Cardiac Surgery 1998 ·Circulation ·Leo M.G. van de Watering, J. Hermans, J. G. A. Houbiers, Pieter J. van den Broek, (unknown), F. Boer, Mark S. Harvey, Hans A. Huysmans, Anneke Brand	414
7	Coagulation parameters of CPD fresh‐frozen plasma and CPD cryoprecipitate‐poor plasma after storage at 4°C for 28 days 1993 ·Transfusion ·(unknown), Mark S. Harvey, E Briët, Anneke Brand	29
8	Misleading Results in the Determination of Haemolytic Disease of the Newborn Using Antibody Titration and ADCC in a Woman with Anti‐Lub 1992 ·Vox Sanguinis ·V.M.J. Novotný, H. H. H. Kanhai, M.A.M. Overbeeke, (unknown), Mark S. Harvey, Anneke Brand	5
9	Transfusion Results of Filtered and Subsequently Stored Random Platelet Suspensions Prepared from Buffy Coats 1992 ·Vox Sanguinis ·V.M.J. Novotný, (unknown), (unknown), J. D’Amaro, Mark S. Harvey, Anneke Brand	23
10	Phospholipid Exchange between Membranes 1974 ·Journal of Biological Chemistry ·George M. Helmkamp, Mark S. Harvey, K.W.A. Wirtz, L.L.M. Van Deenen	222
11	Influence of membrane phosphatidylinositol content on the activity of bovine brain phospholipid transfer protein 1974 ·FEBS Letters ·Mark S. Harvey, George M. Helmkamp, K.W.A. Wirtz, L.L.M. Van Deenen	27
12	A study of phospholipid exchange proteins present in the soluble fractions of beef liver and brain 1973 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Mark S. Harvey, K.W.A. Wirtz, H.H. Kamp, B.J.M. Zegers, L.L.M. Van Deenen	35
13	EVALUATION OF CLINICAL METHODS FOR DETECTING PROTEINURIA 1967 ·The Lancet ·(unknown), H. Keen, (unknown), Mark S. Harvey, Michael Field, (unknown)	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact